MP4 molecule is an investigational biopharmaceutical product designed to enhance the perfusion and oxygenation of oxygen-deprived tissues and provide targeted oxygen delivery to the capillaries in severely injured trauma patients.
Sangart is expected to utilise the fund for further pre-clinical development of the MP4 molecule in traumatic hemorrhage and ischemia in support of its current and future clinical programs.
Sangart president and CEO Brian O’Callaghan said that the grant supports their efforts in continuing the development of medicines designed to enhance the delivery of oxygen to tissues and organs that are oxygen deprived.